Capra Biosciences Wins $17M for US Pharma Production

Capra Biosciences has secured a significant federal grant totaling $17 million to bolster domestic production of critical pharmaceutical ingredients. This funding, awarded by the U.S. Department of Health and Human Services' Center for Industrial Base Management and Supply Chain, part of ASPR, is earmarked for establishing U.S.-based manufacturing capabilities for acetaminophen and six other essential Active Pharmaceutical Ingredients (APIs) currently reliant on foreign supply chains, predominantly from China.

The strategic investment underscores a national imperative to re-shore pharmaceutical manufacturing, reducing reliance on overseas sources for vital medicines. The U.S. biopharmaceutical sector is increasingly focused on supply chain resilience, a trend amplified by recent global disruptions. This initiative aligns with a broader federal commitment, through ASPR’s BioMaP-Consortium, to revitalize domestic biomanufacturing capacity for essential medications, representing a substantial $20 billion national effort.

Virginia-based Capra Biosciences distinguishes itself through an innovative "scale-out" manufacturing approach. Instead of concentrating production in large, single-product facilities, the company employs a modular system of parallel bioreactors, each integrated with purification capabilities from the outset. This proprietary, microbe-based technology allows for flexible feedstock utilization, accommodating sources like glucose, glycerol, or byproducts from ethanol production, a departure from conventional manufacturing methods. This adaptable model facilitates distributed manufacturing that can be replicated regionally as demand evolves.

The company has demonstrated rapid development, successfully scaling pilot production for aspirin and acetaminophen within two years, a pace considered swift for the industry. Their process development and strain engineering benefited from collaboration with A-Life, an entity associated with Google X. With this new federal funding, Capra Biosciences intends to expand its portfolio by developing five additional APIs, further diversifying its domestic production capabilities.

This award positions Capra Biosciences as a key player in the national strategy to fortify pharmaceutical supply chains. The company's unique technological platform offers a compelling solution for decentralized, agile API production. Beyond this federal grant, Capra Biosciences is backed by notable investors including SOSV, DCVC, and Lowercarbon Capital, reflecting strong private sector confidence in their innovative model. Previous collaborations and funding rounds involving entities like Bristol Myers Squibb and Sanofi also highlight the company's established presence and potential within the pharmaceutical ecosystem.